Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer

Int J Cancer. 2002 Mar 1;98(1):45-50. doi: 10.1002/ijc.10145.


The prognosis of pancreatic cancer is extremely poor with a 5-year survival of approximately 3%. Thus, the development of new treatment modalities, including a specific immunotherapy, is required. Our study investigated whether cytotoxic T-lymphocyte (CTL) precursors reacting to peptides with vaccine candidates (13 peptides for HLA-A2+ or -A24+ patients, respectively) were detectable in the prevaccination peripheral blood mononuclear cells (PBMCs) of 15 pancreatic cancer patients. Peptide-specific CTL precursors were detectable in the majority (11 of 15, 73%) of patients, with a mean positive number of 1.5 peptides (ranging from 0-5 peptides) per patient. Positive peptide profiles varied among patients. These results may provide a scientific basis for a new kind of cancer immunotherapy, namely, a CTL precursor-oriented peptide vaccine, for pancreatic cancer patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm
  • Cancer Vaccines / immunology
  • DNA-Binding Proteins*
  • HLA-A Antigens / analysis*
  • HLA-A2 Antigen / analysis*
  • HLA-A24 Antigen
  • Hematopoietic Stem Cells / immunology*
  • Humans
  • Immunotherapy
  • Neoplasm Proteins
  • Pancreatic Neoplasms / immunology*
  • Pancreatic Neoplasms / therapy
  • RNA-Binding Proteins
  • Ribonucleoproteins, Small Nuclear*
  • T-Lymphocytes, Cytotoxic / immunology*


  • Antigens, Neoplasm
  • Cancer Vaccines
  • DNA-Binding Proteins
  • HLA-A Antigens
  • HLA-A2 Antigen
  • HLA-A24 Antigen
  • Neoplasm Proteins
  • RNA-Binding Proteins
  • Ribonucleoproteins, Small Nuclear
  • SART1 protein, human
  • SART3 protein, human
  • DSE protein, human